Intra-Cellular Therapies Inc. (ITCI): Price and Financial Metrics

Intra-Cellular Therapies Inc. (ITCI): $56.96

-1.45 (-2.48%)

POWR Rating

Component Grades













Add ITCI to Watchlist
Sign Up

Industry: Biotech



in industry


  • ITCI scores best on the Sentiment dimension, with a Sentiment rank ahead of 54.19% of US stocks.
  • The strongest trend for ITCI is in Stability, which has been heading down over the past 179 days.
  • ITCI ranks lowest in Stability; there it ranks in the 10th percentile.

ITCI Stock Summary

  • ITCI's price/sales ratio is 69.34; that's higher than the P/S ratio of 96.95% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.13 for Intra-Cellular Therapies Inc; that's greater than it is for only 9.9% of US stocks.
  • As for revenue growth, note that ITCI's revenue has grown 267.35% over the past 12 months; that beats the revenue growth of 96.81% of US companies in our set.
  • Stocks that are quantitatively similar to ITCI, based on their financial statements, market capitalization, and price volatility, are SSYS, JAMF, PRLB, ASPN, and AMRS.
  • Visit ITCI's SEC page to see the company's official filings. To visit the company's web site, go to

ITCI Valuation Summary

  • ITCI's price/earnings ratio is -11.4; this is 131.23% lower than that of the median Healthcare stock.
  • Over the past 93 months, ITCI's price/earnings ratio has gone up 10363.6.
  • Over the past 93 months, ITCI's EV/EBIT ratio has gone up 8923.4.

Below are key valuation metrics over time for ITCI.

Stock Date P/S P/B P/E EV/EBIT
ITCI 2021-08-31 48.4 4.9 -11.4 -11.0
ITCI 2021-08-30 47.2 4.8 -11.1 -10.7
ITCI 2021-08-27 45.9 4.6 -10.8 -10.4
ITCI 2021-08-26 45.4 4.6 -10.7 -10.3
ITCI 2021-08-25 46.8 4.7 -11.0 -10.6
ITCI 2021-08-24 46.4 4.7 -10.9 -10.5

ITCI Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -45.27%.
  • Its 4 year cash and equivalents growth rate is now at 386.01%.
  • Its year over year price growth rate is now at 96.56%.
ITCI's revenue has moved up $73,383,695 over the prior 15 months.

The table below shows ITCI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 83.80302 -259.5435 -284.1257
2021-09-30 70.58636 -254.6017 -259.0909
2021-06-30 55.74775 -238.914 -237.3665
2021-03-31 37.60783 -226.6136 -232.335
2020-12-31 22.81298 -230.0728 -227.0057
2020-09-30 10.41932 -196.886 -206.8893

ITCI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks.
  • ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks.
  • BHVN, OCX, and BTX are the stocks whose asset turnover ratios are most correlated with ITCI.

The table below shows ITCI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.080 0.907 -0.448
2021-03-31 0.058 0.913 -0.480
2020-12-31 0.038 0.917 -0.536
2020-09-30 0.021 0.928 -0.703
2020-06-30 0.008 0.935 -0.843
2020-03-31 0.003 0.939 -0.803

ITCI Price Target

For more insight on analysts targets of ITCI, see our ITCI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.44 Average Broker Recommendation 1.27 (Strong Buy)

ITCI Stock Price Chart Interactive Chart >

Price chart for ITCI

ITCI Price/Volume Stats

Current price $56.96 52-week high $66.00
Prev. close $58.41 52-week low $28.40
Day low $55.88 Volume 544,400
Day high $58.33 Avg. volume 1,116,673
50-day MA $57.86 Dividend yield N/A
200-day MA $46.22 Market Cap 5.37B

Intra-Cellular Therapies Inc. (ITCI) Company Bio

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company was founded in 2002 and is based in New York, New York.

ITCI Latest News Stream

Event/Time News Detail
Loading, please wait...

ITCI Latest Social Stream

Loading social stream, please wait...

View Full ITCI Social Stream

Latest ITCI News From Around the Web

Below are the latest news stories about Intra-Cellular Therapies Inc that investors may wish to consider to help them evaluate ITCI as an investment opportunity.

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, March 1, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2021. To a

Yahoo | February 22, 2022

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Where Intra-Cellular Therapies Stands With Analysts

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ: ITCI ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $57.0 versus the current price of Intra-Cellular Therapies at $55.53, implying upside. Below is a summary of how these 4 analysts rated Intra-Cellular Therapies over the past 3 months. The greater the number of bullish ratings, the more positive analysts … Full story available on

Benzinga | February 16, 2022

Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:40 am ET.

GlobeNewswire | February 10, 2022

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | January 28, 2022

Read More 'ITCI' Stories Here

ITCI Price Returns

1-mo 7.11%
3-mo 6.33%
6-mo 34.18%
1-year 48.64%
3-year 322.87%
5-year 460.63%
YTD 8.83%
2021 64.59%
2020 -7.32%
2019 201.23%
2018 -21.34%
2017 -4.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5241 seconds.